237 related articles for article (PubMed ID: 25304014)
1. Effect of CYP2C9, CYP4F2 and VKORC1 genetic polymorphisms on pharmacokinetics and pharmacodynamics of mean daily maintenance dose of warfarin in Chinese patients.
Zhuang W; Wen W; Xuan B; Chen Y; Cao Y; Sun Z; Ma J
Blood Coagul Fibrinolysis; 2015 Mar; 26(2):167-74. PubMed ID: 25304014
[TBL] [Abstract][Full Text] [Related]
2. CYP4F2 rs2108622: a minor significant genetic factor of warfarin dose in Han Chinese patients with mechanical heart valve replacement.
Cen HJ; Zeng WT; Leng XY; Huang M; Chen X; Li JL; Huang ZY; Bi HC; Wang XD; He YL; He F; Zhou RN; Zheng QS; Zhao LZ
Br J Clin Pharmacol; 2010 Aug; 70(2):234-40. PubMed ID: 20653676
[TBL] [Abstract][Full Text] [Related]
3. Responsiveness to low-dose warfarin associated with genetic variants of VKORC1, CYP2C9, CYP2C19, and CYP4F2 in an Indonesian population.
Rusdiana T; Araki T; Nakamura T; Subarnas A; Yamamoto K
Eur J Clin Pharmacol; 2013 Mar; 69(3):395-405. PubMed ID: 22855348
[TBL] [Abstract][Full Text] [Related]
4. Plasma vitamin K concentrations depend on CYP4F2 polymorphism and influence on anticoagulation in Japanese patients with warfarin therapy.
Hirai K; Yamada Y; Hayashi H; Tanaka M; Izumiya K; Suzuki M; Yoshizawa M; Moriwaki H; Akimoto T; Tsuji D; Inoue K; Itoh K
Thromb Res; 2015 May; 135(5):861-6. PubMed ID: 25747538
[TBL] [Abstract][Full Text] [Related]
5. CYP4F2 gene polymorphism as a contributor to warfarin maintenance dose in Japanese subjects.
Nakamura K; Obayashi K; Araki T; Aomori T; Fujita Y; Okada Y; Kurabayashi M; Hasegawa A; Ohmori S; Nakamura T; Yamamoto K
J Clin Pharm Ther; 2012 Aug; 37(4):481-5. PubMed ID: 22172097
[TBL] [Abstract][Full Text] [Related]
6. Effect of CYP2C9, VKORC1, CYP4F2 and GGCX genetic variants on warfarin maintenance dose and explicating a new pharmacogenetic algorithm in South Indian population.
Krishna Kumar D; Shewade DG; Loriot MA; Beaune P; Balachander J; Sai Chandran BV; Adithan C
Eur J Clin Pharmacol; 2014 Jan; 70(1):47-56. PubMed ID: 24019055
[TBL] [Abstract][Full Text] [Related]
7. Prediction of warfarin maintenance dose in Han Chinese patients using a mechanistic model based on genetic and non-genetic factors.
Lu Y; Yang J; Zhang H; Yang J
Clin Pharmacokinet; 2013 Jul; 52(7):567-81. PubMed ID: 23515956
[TBL] [Abstract][Full Text] [Related]
8. [Influence of warfarin related genes and non- genetic factors on administrative dose in Shanghai area].
Zhuang W; Wu D; Wang Z
Zhonghua Xue Ye Xue Za Zhi; 2014 Jan; 35(1):13-7. PubMed ID: 24602724
[TBL] [Abstract][Full Text] [Related]
9. Impact of CYP2C9*3, VKORC1-1639, CYP4F2rs2108622 genetic polymorphism and clinical factors on warfarin maintenance dose in Han-Chinese patients.
Liang R; Li L; Li C; Gao Y; Liu W; Hu D; Sun Y
J Thromb Thrombolysis; 2012 Jul; 34(1):120-5. PubMed ID: 22528326
[TBL] [Abstract][Full Text] [Related]
10. Effect of VKORC1, CYP2C9, CFP4F2, and GGCX Gene Polymorphisms on Warfarin Dose in Japanese Pediatric Patients.
Wakamiya T; Hokosaki T; Tsujimoto S; Kadota K; Nakano Y; Watanabe S; Iwamoto M; Yanagimachi M; Ito S
Mol Diagn Ther; 2016 Aug; 20(4):393-400. PubMed ID: 27262824
[TBL] [Abstract][Full Text] [Related]
11. A new algorithm to predict warfarin dose from polymorphisms of CYP4F2 , CYP2C9 and VKORC1 and clinical variables: derivation in Han Chinese patients with non valvular atrial fibrillation.
Wei M; Ye F; Xie D; Zhu Y; Zhu J; Tao Y; Yu F
Thromb Haemost; 2012 Jun; 107(6):1083-91. PubMed ID: 22534826
[TBL] [Abstract][Full Text] [Related]
12. Effect of CYP2C9, VKORC1, and CYP4F2 polymorphisms on warfarin maintenance dose in children aged less than 18 years: a protocol for systematic review and meta-analysis.
Takeuchi M; Kobayashi T; Brandão LR; Ito S
Syst Rev; 2016 Jun; 5(1):105. PubMed ID: 27334984
[TBL] [Abstract][Full Text] [Related]
13. Pharmacogenetics of Warfarin in a Diverse Patient Population.
Mak M; Lam C; Pineda SJ; Lou M; Xu LY; Meeks C; Lin C; Stone R; Rodgers K; Mitani G
J Cardiovasc Pharmacol Ther; 2019 Nov; 24(6):521-533. PubMed ID: 31064211
[TBL] [Abstract][Full Text] [Related]
14. Influence of CYP2C9, VKORC1, and CYP4F2 polymorphisms on the pharmacodynamic parameters of warfarin: a cross-sectional study.
Sridharan K; Al Banna R; Malalla Z; Husain A; Sater M; Jassim G; Otoom S
Pharmacol Rep; 2021 Oct; 73(5):1405-1417. PubMed ID: 33811620
[TBL] [Abstract][Full Text] [Related]
15. Influence of CYP4F2 polymorphisms and plasma vitamin K levels on warfarin sensitivity in Japanese pediatric patients.
Hirai K; Hayashi H; Ono Y; Izumiya K; Tanaka M; Suzuki T; Sakamoto T; Itoh K
Drug Metab Pharmacokinet; 2013; 28(2):132-7. PubMed ID: 22892446
[TBL] [Abstract][Full Text] [Related]
16. Genetic epidemiology of pharmacogenetic variations in CYP2C9, CYP4F2 and VKORC1 genes associated with warfarin dosage in the Indian population.
Giri AK; Khan NM; Grover S; Kaur I; Basu A; Tandon N; Scaria V; ; ; Kukreti R; Brahmachari SK; Bharadwaj D
Pharmacogenomics; 2014 Jul; 15(10):1337-54. PubMed ID: 25155935
[TBL] [Abstract][Full Text] [Related]
17. The impact of non-genetic and genetic factors on a stable warfarin dose in Thai patients.
Wattanachai N; Kaewmoongkun S; Pussadhamma B; Makarawate P; Wongvipaporn C; Kiatchoosakun S; Vannaprasaht S; Tassaneeyakul W
Eur J Clin Pharmacol; 2017 Aug; 73(8):973-980. PubMed ID: 28550460
[TBL] [Abstract][Full Text] [Related]
18. Variation in genes controlling warfarin disposition and response in American Indian and Alaska Native people: CYP2C9, VKORC1, CYP4F2, CYP4F11, GGCX.
Fohner AE; Robinson R; Yracheta J; Dillard DA; Schilling B; Khan B; Hopkins S; Boyer B; Black J; Wiener H; Tiwari HK; Gordon A; Nickerson D; Tsai JM; Farin FM; Thornton TA; Rettie AE; Thummel KE
Pharmacogenet Genomics; 2015 Jul; 25(7):343-353. PubMed ID: 25946405
[TBL] [Abstract][Full Text] [Related]
19. A network meta-analysis of CYP2C9, CYP2C9 with VKORC1 and CYP2C9 with VKORC1 and CYP4F2 genotype-based warfarin dosing strategies compared to traditional.
Sridharan K; Sivaramakrishnan G
J Clin Pharm Ther; 2021 Jun; 46(3):640-648. PubMed ID: 33346393
[TBL] [Abstract][Full Text] [Related]
20. [Impact of six genetic polymorphisms on Warfarin maintenance dose variation in Chinese Han population].
Lou Y; Han L; Li Y; Zhang X; Liu Z; Tang M; Yu H; Wang W; Xu J; Liu H; Li Y
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2014 Jun; 31(3):367-71. PubMed ID: 24928022
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
